期刊
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
卷 41, 期 3, 页码 489-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2015.04.009
关键词
Systemic sclerosis; Pulmonary arterial hypertension; Monitoring; Diagnosis
类别
资金
- Gilead
- United Therapeutics
- Pfizer
- Actelion
- Scleroderma Research Foundation
- Scleroderma Foundation
Pulmonary arterial hypertension (PAH) is one of the leading causes of death in patients with systemic sclerosis (SSc). Given the high prevalence and poor survival of SSc-PAH, and that aggressive management of mild disease may be associated with better outcomes, screening is critical. Right heart catheterization (RHO) is the gold standard for the definitive diagnosis of PAH, and should be performed in those patients in whom this diagnosis is suspected. Once a diagnosis of PAH is confirmed by RHO, treatment with PAH-specific therapies should be initiated as soon as possible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据